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ABSTRACT
Despite evidence that bacterial vaginosis can lead to poor perinatal outcomes the
consensus remains against a screening and treatment protocol for all pregnant women. Due to
variability in a multitude of factors, a generalized recommendation is difficult to make. There are
inconsistencies among stage of gestation that screening took place and treatment selection. The
multiple variables in demographics also make providing best practice recommendations difficult.
Lack of recommendations are largely due to harm of treatment in those who were
misdiagnosed. The development of polymerase chain reaction (PCR) has the capability to reduce
misdiagnosis. Newer studies have shown benefit of early screening and treatment and the use of
clindamycin over the traditional treatment of metronidazole.
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INTRODUCTION
Bacterial vaginosis (BV) occurs when there is a disruption of the normal flora present in
the vagina. This is caused by an overgrowth of anaerobic bacteria and a decrease of the normal
flora; Lactobacilli. Pathogen bacteria can include Gardenella Vaginalis, Mobiluncus species,
Bacteroides, Prevotella species, and Mycoplasma species (Van Schalkwyk & Yudin, 2015).
Disruption of the normal flora can occur for a variety of reasons; all of which are not completely
understood. Bacterial vaginosis is the most common vaginal infection in women of reproductive
age (Nygren, Fu, Freeman, Bougatsos, Klebanoff, Guise, 2008). Yudin & Money (2017) address
that chorioamnionitis, preterm delivery, preterm rupture of membranes, and late miscarriage
have all been associated with positive bacterial vaginosis during pregnancy. Despite extensive
research showing this correlation, researchers have not been able to show a promising method
for screening and treatment to improve outcomes. Significant contributing factors to this problem
are the multiple variables in the demographics, diagnosis method, treatment modalities, and age
of gestation when screening and treatment occurs.
Another contributing factor that makes recommendations difficult is that BV is present in
20-50% of women during pregnancy and most of these cases are asymptomatic (Brocklehurst,
Gordon, Heatley, Milan, 2013). It is also known that up to 50% of BV cases clear without
treatment. However, there is a possibility that it may recur after treatment. Knowing which
infections will clear on their own and which will cause harm is undeterminable at this time. The
current research shows that BV is more prevalent among minority women; African American in
particular, those of low socioeconomic status, smokers, those with increased sexual partners, and
women who have had previously delivered low birth weight infants (Nygren et al, 2008). To
decrease poor perinatal outcomes; should all pregnant women be screened for BV and at what
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stage of pregnancy? This is a question that researchers still have been unable to find a best
practice answer for.
The 2008 USPSTF guidelines recommend against routine screening of pregnant women
for BV. Recommendations were based on lack of consistent benefit and possible risk of harm
(Nygren et al., 2008). Current CDC (2015) guidelines state, “Therefore, evidence is insufficient
to recommend routine screening for BV in asymptomatic pregnant women at high or low risk for
preterm delivery for the prevention of preterm birth” (Workowski & Bolan, 2015, p.71). The
American College of Obstetricians and Gynecologists (ACOG), The Society of Obstetricians and
Gynaecologists of Canada (SOGC), and The American Academy of Family Physicians (AAFP)
all recommend against routine screening and treatment of BV in asymptomatic pregnant patients.
SOGC does support the screening and treatment of those at high-risk and to complete the
screening between 12- and 16-weeks’ gestation (Yudin & Money, 2017). USPSTF defines highrisk as those with previous preterm delivery due to spontaneous rupture of membranes or
spontaneous preterm labor. Low-risk was defined as no previous preterm delivery and no
additional risk factors for preterm delivery (Nygren et al., 2008). Traditionally, the diagnostic
methods have been clinically with Amsel’s criteria or microbiologically with Nugent’s gram
stain. Intermediate flora which is a Nugent score of 4-7, has also been associated with adverse
pregnancy outcomes (McNamee, Dawood, & Farquharson, 2014). All studies referenced for this
paper used one of these methods. As mentioned above, there is variability in not only screening
recommendations, but also treatment recommendations. CDC’s first line treatments for BV
positive pregnant women are oral metronidazole 250 mg three times daily for 7 days or
clindamycin 300 mg orally twice daily for 7 days (Workowski & Bolan, 2015). SOGC states
treatment with either oral or vaginal antibiotics are acceptable for cure, but if prevention of

Running head: SCREENING FOR BACTERIAL VAGINOSIS IN PREGNANCY

7

adverse pregnancy outcomes is desired, only oral preparations should be used. Their
recommendation is the same for clindamycin, but their recommendation for metronidazole is 500
mg twice daily for seven days. Yudin & Money (2017) addresses that these treatment modalities
have shown only moderate success and recurrence rates are high. Repeat testing is recommended
following treatment.
Alteration in vaginal flora increases risk for acquiring other sexually transmitted diseases;
Trichomonas vaginalis and Chlamydia trachomatis. They have both been shown to increase rates
of premature rupture of membranes and preterm labor (McNamee, 2014). Higher rates of
Mobiluncus is associated with a higher Nugent score of 9-10 and one study found it to be
associated with an increased incidence among asymptomatic patients (Nelson, Bellamy,
Nachamkin, Ruffin, Allen-Taylor, & Friedenberg, 2008). Clindamycin has a broader range
against atypical mycoplasma and Mobiluncus compared to the traditional treatment of
metronidazole (Ugwumadu, Manyonda, Reid, & Hay, 2003).
The purpose of this scholarly project is to answer the question of which pregnant patients
should be screened for BV and does identification and treatment of BV during pregnancy
improve perinatal outcomes.
Statement of the Problem
BV is the most common lower genital tract syndrome in women of reproductive age
(Nygren et al., 2008). Research has shown that BV is linked to poor perinatal outcomes. There
are varying opinions on which pregnant patients should be screened for BV and what treatments
should be used.
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Research Question
It is well known that BV can cause pregnancy complications but there remains no
consensus on whether all pregnant women should be screened and treated for BV. Would
screening and treatment for asymptomatic BV improve perinatal outcomes?
LITERATURE REVIEW
A review of the literature yielded several high-quality meta-analyses, systematic reviews,
random control trials, and cohort studies. Studies were limited to those published in 2008 or
later. Searches were completed in PubMed, CINHAL, and Cochrane Database. Additional
sources were found using reference lists. Search terms utilized included; bacterial vaginosis,
vaginitis, pregnancy, pregnant, miscarriage, screening, pre-term, and asymptomatic. Excluded
studies included those that did not discuss effects of bacterial vaginosis on pregnancy. Studies
were limited to those with high levels of evidence regarding bacterial vaginosis and that did not
include conflict of interest.
Background information and current guidelines
Nygren et al. (2008) reviewed the previous USPSTF recommendations from 2001 and combined
that with seven new random control trials to evaluate the benefits and harms of screening
asymptomatic pregnant patients for bacterial vaginosis. A search was done using Englishlanguage studies on MEDLINE from 2000 – September 2007 and from Cochrane Library
databases through September 2007. Additional searches were done using reference lists
and expert suggestions. Study selection was done by two reviewers and was limited to
systematic reviews and individual random control trials. No studies were found
comparing a screened vs. non-screened population.
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Asymptomatic was defined as women who were being seen for routine prenatal care not
specifically evaluation of vaginal symptoms. Using this criterion; patients who were
unaware of symptoms that met criteria for bacterial vaginosis were included. Patients
were categorized in low, general, or high-risk categories. High-risk qualifications were
defined as previous preterm delivery due to spontaneous rupture of membranes or
spontaneous preterm labor. Low-risk was defined as no previous preterm delivery and no
additional risk factors for preterm delivery. The studies that qualified their participants as
average risk included both low and high-risk women and the goal was to get a better
picture of the general population. Patients with additional symptomatic infections were
excluded; but some participants were found to have co-infection upon screening and
these women were still included. Meta-analyses were done including new trials in
addition to the ones used in the 2001 review. The primary outcome was the absolute risk
reduction of preterm delivery prior to 37 weeks in treatment of bacterial vaginosis
between the control and treatment group. Of the new studies; three looked at low-risk
women, four used average-risk; general population, and one recruited women who
qualified as high-risk. Studies took place in six different countries and used a variety of
treatment regimens. There was also variability in rescreening and additional rounds of
treatment given. Despite the variability, the addition of new studies still showed no
benefit to screening and treatment of asymptomatic pregnant patients in low or averagerisk categories. As for the high-risk group, conflicting evidence was found as three out of
five studies showed benefit with treatment, but one showed treatment harm and another
no benefit. Of the studies currently available, there is wide variability of patients involved
and their risk level, timing of screening, diagnostic criteria, and treatment modalities.
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Some studies have reported adverse effects to the standard treatment regimen of using
metronidazole and so it has become a question of whether further studies are able to be
done (Nygren et al. 2008).
Van Schalkwyk and Yudin (2015) conducted a review of the literature from MEDLINE,
EMBASE, CINAHL, and the Cochrane Library up to May 2014 was done to provide
recommendations on screening and management of vaginitis; bacterial vaginosis
included. This was an update of the Society of Obstetricians and Gynaecologists of
Canada (SOGC) clinical practice guidelines. The search was restricted to systematic
reviews, randomized control trials, controlled clinical trials, and observational studies.
English and French were the only languages selected and there were no date restrictions.
The guideline was prepared by an infectious disease committee and then reviewed by the
Family Physician Advisory Committee.
BV is the most common lower genital tract infection of both pregnant and non-pregnant
women. Its prevalence has been linked to a variety of complications; preterm labor and
delivery, preterm premature rupture of membranes, spontaneous abortion. As well as,
postpartum effects on both mom and baby, including endometritis, post-cesarean wound
infections, and subclinical pelvic inflammatory disease. There appears to be a higher
incidence among black women, those who smoke, and those who use vaginal douches or
intravaginal products. BV is not a sexually transmitted disease, but its incidence increases
among those with and increased number of sexual partners, as well as those who engage
in sexual intercourse more frequently. Lactobacillus is the predominant species found in
normal vaginal flora. It should account for greater than 95% of the bacteria present. BV
occurs when normal flora is disrupted; allowing for pathogenic bacteria to thrive. The
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diagnosis of BV is traditionally done clinically using Amsel’s criteria. Criteria diagnosis
can be made with three of the four following signs; adherent and homogenous vaginal
discharge, vaginal pH greater than 4.5, detection of clue cells, and amine odor after
addition of KOH (positive whiff test). The most common microbiologic method used is
Nugent’s Criteria. This method quantifies the number of Lactobacillus and pathogenic
bacteria. Results are scored from 0-10. 0-3 being normal, 4-6 considered intermediate
flora, and 7-10 meets criteria for the diagnosis of BV. It has been shown that up to onethird of women who are treated have a recurrence of BV within three months. Currently,
treatment is recommended for only those with symptomatic BV. First line treatment is
oral metronidazole 500 mg twice daily for seven days. Alternatives include, intravaginal
metronidazole or intravaginal or oral clindamycin. These treatments have produced
moderate success with cure and high rates of recurrence are still seen (Van Schalkwyk &
Yudin, 2015).
Yudin and Money (2017) conducted a review of the English literature using MEDLINE,
EMBASE, CINAHL, and Cochrane databases up to June 2007. The guideline was again
reviewed by SOGC’s Infectious Disease Committee in March of 2015 and was
reaffirmed for continued use. There remains no consensus for screening or treatment for
bacterial vaginosis in the general population of pregnant patients. Currently, SOGC states
there is fair evidence (I-B) that asymptomatic women and women without identified risk
factors for preterm birth should not undergo routine screening for or treatment of BV.
They also state fair evidence (I-B) that if treatment is chosen and the goal is prevention of
adverse pregnancy outcomes, it should be done with 500 mg metronidazole orally twice
daily for seven days or clindamycin 300 mg orally twice daily for seven days. Vaginal
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therapy is not recommended for the indication of preventing adverse pregnancy outcomes
(I-B). There is currently insufficient evidence (III-L) for rescreening one month after
treatment (Yudin & Money, 2017).
Incidence rate of bacterial vaginosis and poor perinatal outcomes; miscarriage and
preterm birth
Koumans et al. (2011) conducted a retrospective cohort study of Syracuse Healthy Start’s
Program to evaluate outcomes of screening prior to 22 weeks gestation, treatment, and
rescreening for BV. Charts from live births between the dates of January 2000 and March
2002 were abstracted. The data cohort consisted of women who were living in high infant
mortality zip codes in the Syracuse area. A total of 838 women were screened prior to 22
weeks gestation. Outcomes were compared between screened women who had BV or
abnormal flora and were treated vs when no treatment was documented vs those who had
normal flora. Screening for Chlamydia, Gonorrhea, and bacteriuria was also done. All
swabs were sent to the same facility and were interpreted by trained laboratory
technicians. As part of the program, providers were encouraged to treat abnormal flora,
rescreen in 4-6 weeks, and retreat if abnormal flora or BV remained. Data was abstracted
via chart reviews and was done so by blinded reviewers. Reviewers were from the major
delivery hospital’s nursing or clinical staff and took a training course prior. Premature
delivery was defined as birth prior to 37 weeks gestation and extremely premature was
defined as birth prior to 28 weeks gestation. Statistical analysis was done using student’s
t-test, ANOVA for continuous variables, and chi-squared tests for discrete and
dichotomous variables, as appropriate. Bivariate and multivariate logistic regression was
used to examine association between numerous variables. Similarities among those who
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delivered early were; 29 years of age or older, 1st prenatal visit in the 2nd trimester,
previous preterm birth, and a correlation with certain prenatal care providers. Average
age of gestation at initial screening was 11.8 weeks with a standard deviation (SD) of 4.8.
Some women were only screened once, and others were re-screened three or more times.
Initial screening found 406 (48%) had abnormal flora or BV. Those who screened
positive for abnormal flora or BV were more likely to be black, younger than 30, not
married, smokers, education level of high school or less, have more than two children,
and enrolled in Syracuse Healthy Start (SHS) and Women Infants and Children (WIC).
There were also higher incidence rates at certain prenatal care sites. There was variability
among treatment options; some were given 500 mg metronidazole twice daily for 7 days
(59%), 250 mg of metronidazole three times daily for 7 days (19%), 2 gm metronidazole
once (12%), intravaginal metronidazole for 5 days (9%), and intravaginal clindamycin
(2%). Women who were treated for abnormal flora or BV had improved outcomes vs
those who were not treated and had abnormal flora or BV; OR 0.4, 95% CI 0.2-0.7. There
was no statistical significance for preterm delivery between women with normal flora vs
those who were treated for abnormal flora or BV. Those who were positive for abnormal
flora or BV had some commonalities; race, marital status, education level, and
socioeconomic status. This study did not decipher between asymptomatic and
symptomatic patients as all patients were screened regardless of symptoms. Other
limitations of this study included a variety of treatments used, the decision of the provider
to screen and treat, treatments not being recorded in the medical record, and the potential
for medications not being taken as prescribed. Only looking at live births, they did not
extract data on abnormal flora or BV effecting miscarriage. This study did show that
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screening prior to the fusion of the decidua, which usually takes place between 14 and16
weeks shows promise in decreasing the rates of preterm delivery (Koumans et al., 2011).
McNamee et al. (2014) conducted a retrospective study looking at causes of mid-trimester
pregnancy loss. Infection appears to play a larger role in miscarriage during mid-trimester
compared to first trimester. Mid-trimester is defined as loss between 12- and 24-weeks’
gestation. This time period is often overlapped with first trimester loss, preterm delivery
(PTD), or preterm prelabor rupture of membranes (PPROM). According to a
retrospective study including 7000 spontaneous deliveries; chorioamnionitis was present
in 94% prior to 24 weeks gestion, 40% between 25 and 28 weeks, and 11% after 33
weeks. BV which is an alteration in vaginal flora, increases risk for acquiring other
sexually transmitted diseases; Trichomonas Vaginalis and Chlamydia Trachomatis which
have both been shown to increase rates of premature rupture of membranes and preterm
labor as well. The use of clindamycin for BV or intermediate vaginal flora has been
shown to reduce mid-trimester loss. Both oral and vaginal cream show promise but
screening and treatment needs to be done early. Without a history of mid-trimester
pregnancy loss or preterm delivery there is limited data to support screening of the
general obstetric community (McNamee et al., 2014).
Nelson et al. (2008) conducted a cohort study of 1916 pregnant women, over 30 months, who
were 12 weeks gestation or less was done to help determine what clinical, behavioral, or
demographic factors play a role in asymptomatic BV. The study also compared
pregnancy outcomes of those with who were asymptomatic to those who were BV
positive and symptomatic. Specifically looking at prior prelabor rupture of membranes
(PPROM), spontaneous preterm delivery (SPTD), and low birth weight (LBW).

Running head: SCREENING FOR BACTERIAL VAGINOSIS IN PREGNANCY

15

Participants were all patients of the obstetrics department at the Hospital of the
University of Pennsylvania between September 2001 and June 2004. Gestation was based
on report of last menstrual period and all women were required to reside in Philadelphia
to be qualified for the study. Excluded were those who did not speak English, multiple
gestations, those found to be farther along than 12 weeks, or who had an ectopic or molar
pregnancy. A total of 1916 women were enrolled and 754 tested positive for BV. Nugent
criteria was used for diagnosis. Those with values of seven to ten were included. Those
with normal or intermediate flora were excluded. Of the two sites recruiting participants,
one provided care to only privately insured women; 53% and other for publicly insured;
47%. All participants had a vaginal swab collected at their first prenatal visit; 53% were
self-collected. A questionnaire was also required which included questions on
demographics, prior and current obstetric and gynecologic history, vaginal bleeding,
vaginal symptoms, current and past feminine hygiene and health behaviors as well as
history regarding sexual practices, sexually transmitted diseases, past or current alcohol
and drug use and perceived stress in the prior one month. Stress was measured using
Cohen’s perceived stress scale. The questionnaire was facilitated by a female nurse in a
confidential setting. All interviewers, abstractors, and obstetricians were blinded to the
Gram stain results. To categorize previous pregnancy outcomes; medical records were
abstracted. Those defined as symptomatic reported either abnormal vaginal odor or
abnormal vaginal discharge since last menstrual period (LMP). Risk factors for testing
positive were African American, lower social economic status, earlier sexual activity,
higher psychosocial stress, history of vaginal douching, and history of cigarette use. Of
those who tested positive, 66.6% were asymptomatic. The results found a weak
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relationship between asymptomatic BV and less stress RR 0.78; CI 0.67-0.89, history of
at least one STD RR 1.03, 95% CI: 1.01-1.07, and higher quantity of the Mobiluncus
bacteria RR 1.04, 95% CI 1.01-1.07. Symptomatic BV positive women had a slightly
higher Nugent score compared to the asymptomatic group; p=0.05. This study showed a
similar incidence of PPROM, SPTD, and LBW in both asymptomatic and symptomatic
patients (Nelson et al., 2008).
The study did not address if treatment was done or what treatment modality was used.
Screening of co-existing STDs or Candida was not done. The questionnaire used to
evaluate stress level was validated in African American women but not in pregnant
women. Higher scores on the Cohen scale were correlated with current unemployment,
non-married women, and those with a lower education level. The cohort of this study is
not a good representation of the general population. Despite self-collection being
documented as a reliable and valid way of sample collection; all swabs were not
collected in the same way.
Usher-Pines, Hanlon, and Nelson, (2009) conducted a prospective cohort study of 1,886 pregnant
women. It was done to help determine predictors of BV and BV-related microorganisms
by racial group. The population consisted of urban African American and non-African
American women in their first trimester. Those in the non-African American group were
60% white and 20% Asian. BV was measured using Nugent Gram Stain criteria.
Smoking was evaluated by urine cotinine levels and stress using Cohen’s perceived stress
scale. Participants were all patients of the obstetrics department at the Hospital of the
University of Pennsylvania between September 2001 and June 2004. Gestation was based
on report of last menstrual period and all women were required to reside in Philadelphia
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to be qualified for the study. Excluded were those who did not speak English, had
multiple gestations, those found to be farther along than 12 weeks, or who had an ectopic
or molar pregnancy. The primary outcomes were to determine predictors of BV and to
evaluate BV status and levels of the three common BV-related microorganisms;
Lactobacillus, Mobiluncus, and Bacteroides/Gardnerella. A Nugent score of 7-10 met
criteria for BV. Quantities of each bacteria were graded 0-4, 4 being the highest level; 30
or more organisms per oil immersion field. Stress was evaluated at enrollment and again
at 20 weeks gestation. Smokers were identified with a urinalysis cotinine value greater
than 500 ng/ml. This indicates use of cigarettes in the past 72 hours. Private vs
government or uninsured was used to classify socio-economic status. Total number of
sexual partners and previous STDs used to quantify higher risk sexual practices. Vaginal
bleeding and African-American race were both self-reported yes or no questions.
Statistical analysis was done using Chi-square and t-tests for behavior, demographic, and
pregnancy outcomes. Additional models were used when comparing levels of each
microorganism; maternal age, insurance, stress score, douching during pregnancy,
smoking confirmed by urinalysis, history of STD, number of sexual partners, and marital
status. Participants were split up between African American and non-African American.
BV positive predictors were found to be African American race; OR =3.26, 95% CI:
2.29-4.63, unmarried; OR=1.42, 95% CI: 1.00-1.29, smokers; OR=1.72, 95% CI 1.192.50, and reporting of multiple sexual partners; OR =1.13, 95% CI: 1.00-1.29. AfricanAmerican women were found to have lower levels of Lactobacillus compared to nonAfrican American. Women who douched also had lower levels compared to those who
did not. High Mobiluncus & high Gardneralla levels were correlated with African-
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American race, single women, and smokers. Limitations include the method used to
evaluate stress does not include anxiety or stressful life events. The sample population
did not allow for further breakdown beyond non-African American. Only the three
microorganisms used for Nugent criteria were included; others that commonly coexist
were not included. The recurrence of BV was not assessed. This cohort does not represent
the general population. It is unclear if those who were found to have low birth weight
(LBW), spontaneous preterm birth (SPTB), spontaneous preterm labor (sPTL), or
spontaneous abortion (SAB) through medical review were positive or negative for BV
with previous pregnancies. Other studies have shown risk of poor perinatal outcomes
with intermediate flora defined as a Nugent score of 4-6. This particular study did not
abstract the data on those women (Usher-Pines et al. 2009).
Van Oostrum, De Sutter, Meys, and Verstraelen, (2013) conducted a meta-analysis and
systematic review on bacterial vaginosis and infertility. Specifically, they looked at the
prevalence of BV in infertility patients; twelve studies, the association between BV and
the cause of infertility; three studies, effect on conception; six studies, and role in early
preclinical and clinical pregnancy loss; six studies. An initial literature search was done
using MEDLINE from 1966-September 2012. Further searches of EMBASE, CINAHL,
the Cochrane Library, and ISI Web of Knowledge did not yield additional studies. MeSH
terms included were; bacterial vaginosis, Gardnerella, vaginitis, vaginal flora, and
subfertility, infertility, sub fertile, infertile, and IVF. All languages were included. Two of
the authors performed the literature review and data extraction. All studies included used
standardized diagnostic criteria of BV such as Nugent, Hay-lson, or Amsel criteria.
MOOSE guidelines were applied, and raw data was extracted to for calculation based on
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events per women vs. per cycle. Studies included analyzed at least one of the outcome
measures. Outcomes were broken up into four categories; prevalence of BV in infertility,
association of BV with the cause of infertility, conception rate in infertility patients with
BV, and risk of early pregnancy loss in infertility patients with BV. Exclusion was based
on abstract and if at least one outcome measure was not reported on. Subjects for the
studies reviewed were recruited from IVF clinics in varying countries; five in the UK,
two in the US, two in Egypt, one in Republic of Ireland, one in India, and one in the
Netherlands.
The overall incidence of BV and abnormal microflora is higher among infertility patients
compared with antenatal women in the same reference group. The prevalence of BV
among infertile women was 19%; 95% CI: 14-25%. When intermediate flora was
included with BV incidence was 39%; 95% CI 26-52%. Two studies included in this
review found that BV is more prevalent in cases of unexplained infertility. There was a
significant association between BV and preclinical pregnancy loss; 95% CI, p <0.01. The
authors concluded that BV does not affect the rates of conception; OR = 1.03, 0.79-1.33.
However, these results are limited to those women receiving IVF. One disadvantage of
this study is of all those included; none defined fertility but referred to patients that were
attending infertility clinics. None of the studies included had a focus on miscarriage or
preterm birth beyond the first trimester (Van Oostrum et al., 2013).
Treatment of bacterial vaginosis and effect on perinatal outcomes
Brocklehurst et al. (2013) conducted a Cochrane Review to assess antibiotic treatment of BV in
pregnancy. Twenty-one trials were included involving 7847 women with either bacterial
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vaginosis or intermediate flora. The primary outcome was incidence of pregnancy loss
up to 24 weeks’ gestation, otherwise known as a late miscarriage (LM). Additional
outcomes were birth less than 37, 34, and 32 weeks gestation. Also included were
perinatal deaths after 24 weeks and neonatal death up to 28 days. Birthweight was also a
primary outcome. The Cochrane Pregnancy and Childbirth Group’s Trial Registry (31
May 2012) was searched. Cited references from retrieved articles and abstracts, letters to
the editor, and editorials were all reviewed. All languages were included. Two of the
authors searched and reviewed articles for bias. Extensive work was put into the study
assessing for selection, performance, detection, reporting, and attrition bias. Trials used
must have included either comparison of antibiotic treatment with placebo to no
treatment or comparing two different regimens for the treatment of BV. Both
asymptomatic and symptomatic subjects were used. Women at any stage of pregnancy, or
of any age were included. Most of the screening took place in the second trimester; some
studies included results as late as 28 weeks gestation. If there was a coexisting sexually
transmitted disease, this did not exclude them from the studies. Amsel or Nugent criteria
was used for diagnosis. Two trials included intermediate vaginal flora in addition to BV,
these studies were included in a separate comparison. Intermediate flora is defined as a
Nugent score of four to six, a score of seven to ten qualifies as BV. There was a varying
degree between the trials regarding how BV was diagnosed, timing of the treatment, and
the choice of antibiotic for treatment. Choice of treatment varied between the 21 studies.
Nine used oral metronidazole alone, one used oral metronidazole plus erythromycin, one
used oral clindamycin, and one oral amoxicillin. Nine used intravaginal clindamycin and
one vaginal metronidazole gel. The study also broke down the participants into sub
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groups: previous preterm birth; intermediate vaginal flora (including BV), and treatment
before 20 weeks’ gestation. Many, but not all studies excluded women who were
symptomatic. The findings of this study do not provide significant evidence that
screening, and treatment of all pregnant women would yield fewer perinatal
complications. However, areas of screening and treatment at earlier stages as well as
looking to clindamycin compared to metronidazole did show some benefit. At this time,
most studies done have largely focused on metronidazole as treatment.
Overall, antibiotic therapy was effective in eliminating BV during pregnancy; RR 0.42,
95% CI 0.31-0.56 as well as reducing the risk of late miscarriage (LM); RR 0.20, 95% CI
0.05-0.76. The studies that showed a reduction in LM were limited to two trials both
using clindamycin. A total of 1270 women were studied. The results of subgroup analysis
showed no difference in comparison of outcomes between women who did or did not
have a previous preterm birth RR 0.39, 95% CI 0.28-0.53. Only two studies, totaling 894
women included intermediate flora, but did find a reduction in preterm birth less than 37
weeks vs those that did not have altered flora RR 0.53, 95% CI 0.34-0.84. These results
may be attributed to timing of treatment being earlier in gestation (Brocklehurst et al.,
2013).
Haahr et al. (2016) conducted a systematic review to provide clinical recommendations on
treatment of bacterial vaginosis in pregnancy to reduce the risk of preterm delivery. There
is currently no consensus as to whether or not treatment of BV in pregnancy reduces the
risk of spontaneous preterm delivery (sPTD). The goal of this review was to make a
clinical recommendation based on GRADE; strong or weak recommendations. GRADE
quality was determined by risk of bias. Searches were done using Guidelines
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international Network, MEDLINE, EMBASE, The Cochrane Database of Systematic
Reviews, Web of Science from 1999 to October 3, 2014. The national societies of
obstetrics and gynecology from Scandinavia, America, Britain, and Canada were all
searched. At minimum, two members of the guideline group reviewed the search results.
A research librarian assisted the members in their search. Clinical recommendations
address all ages, low and high risk of sPTD, and both asymptomatic and symptomatic
women during pregnancy. For diagnosis; a strong recommendation was made for Nugent
score as the gold standard for diagnosis. Amsel criteria and properly evaluated PCRtechniques may be alternatives. Treatment with metronidazole; a strong recommendation
against treatment of BV positive pregnant women to reduce the risk of sPTD. In high-risk
pregnancies, very low evidence was found that metronidazole reduces risk of PPROM;
RR 0.17, 95% CI 0.04-0.74. In low risk pregnancies RR was 1.11, 95% CI 0.93-1.34.
Treatment with clindamycin; a weak recommendation against treatment of BV in
pregnant women to reduce the risk of sPTD. Treatment at any gestational age had a RR
of 0.87; 95% CI 0.73-1.05. If clindamycin was started before 20 weeks gestation; RR was
0.95; 95% CI 0.71-1.26 (Haar et al. 2016).
Lamont, Duncan, Mandal, & Bassett (2011) conducted a systematic review and metanalysis of
random control trials to determine if administration of clindamycin to women with
abnormal flora and asymptomatic BV at less than 22 weeks of gestation reduced the risk
of preterm birth and late miscarriage. A total of five trails and 2346 patients were
included. Entities searched included; PubMed, EMBASE, CINAHL, and Lilacs all up to
July 21, 2011. The Cochrane Central Register of Controlled Trials, Research Registries
of ongoing trials was also used. All languages were included. Searches were completed
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by two authors. Study selection was based on randomized control trials comparing
treatment of women at <22 weeks gestation with abnormal flora and asymptomatic BV.
Diagnose of BV was based on Gram stains in the first or early second trimester.
Treatment options must have compared either oral clindamycin or clindamycin vaginal
cream (CVC) vs placebo or no intervention. For this review; one study used oral and four
used CVC. Studies included had a primary outcome of preterm birth (delivery <37
weeks). 414 of the 428 potentially relevant citations were excluded based on title or after
review of the abstract. Of those fourteen, only five met criteria and were included in the
analysis. The number needed to treat (NNT) for late miscarriage (LM) is 66. The study
found the administration of Clindamycin at <22 weeks of gestation was associated with a
significant reduction in preterm birth <37 weeks RR 0.60, 95% CI 0.42-86, p<.001,
decreased risk of late miscarriage (birth between 16 and 22 weeks) RR 0.20, 95% CI
0.05-0.76, and significant increase in gestational age at birth 95% CI 0.28-1.01. The route
of clindamycin administration had varying outcomes. The only study that looked at oral
administration showed a 61% reduction in preterm birth <37 weeks; RR 0.73, 95% CI
0.47-1.14. The four studies that looked at CVC showed only a 27% reduction in preterm
birth <37 weeks RR0.73, 95% CI 0.47-1.14. Treatment with oral clindamycin appears to
be more effective in women with a higher Nugent score (10). The comparison here
showed 5.4% rate of PTB or LM, compared to 35.7% in the placebo group. Clindamycin
does carry the risk of clostridium difficile. The vaginal preparation has only 4% systemic
absorption but was found to be less effective than the oral preparation. The wide
variability among trials looking at BV is addressed in this study. Some variations include;
the definition of BV, gestational age at diagnosis and enrollment, the choice of
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antimicrobial agent, dose, and route, follow up on clearance of BV, primary outcomes,
and patient population. At this time, most studies have focused on metronidazole as the
treatment for BV and these studies have not shown significant results. (Lamont et al.,
2011).
Sangkomkamhang, Lumbiganon, Prasertcharoensuk, Laopaiboon, (2015) conducted a Cochrane
review looking at screening and treatment programs for preventing preterm delivery. A
search was done using the Cochrane Pregnancy and Childbirths Group’s Trials Register
up to November 30th, 2014, the Cochrane Central Register of Controlled Trials, and
references lists of retrieved reports. Studies of all languages were included that compared
screening vs no screening of antenatal lower genital tract infections. Two of the authors
assessed all trails for risk of bias, inclusion, extracted data, and checked for accuracy.
One study of 4155 women at less than 20 weeks’ gestation met inclusion criteria. All
participants were asymptomatic. Screening took place between 15- and 19-weeks’
gestation. The study took place in Vienna, Austria. Assessment and risk of bias was done
for each study checking for possible selection, performance, detection, attrition, and
reporting bias. Subgroup analyses were done on early vs late trimester screening and low
risk vs. high risk of preterm birth. All participants of the randomized control trial were
screened using Gram stain. The intervention group received either 2% vaginal
clindamycin for BV or 300 mg clindamycin twice daily for seven days for recurrent BV.
None of the participants reported side effects during treatment. The control groups’ Gram
stain results were not revealed. The primary outcome measured was preterm birth at less
than 37 weeks gestation. This study showed statistically significant evidence that
screening and treatment for antenatal lower genital tract infections reduce preterm birth;
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RR 0.55, 95% CI 0.41-0.75 and, low birth weight infants; RR 0.48, 95% CI 0.34-0.66,
and very low birth weight infants; RR 0.34, 95% CI 0.15-0.75. (Sangkomkamhang et al.
2015).
Workowski & Bolan (2015) updated the sexually transmitted diseases treatment guidelines by
the Center for Disease Control (CDC). This is an update from 2006 guidelines. A
systematic review of the literature was done by CDC staff members looking for new
information published since the 2006 Guidelines were published. Treatment for all
symptomatic pregnant patients is recommended. Recommended treatment from the CDC
remains metronidazole orally 250mg, 500 mg, or intravaginal gel. Clindamycin cream is
also first line. Although metronidazole crosses the placenta, a link between teratogenic or
mutagenic effects on newborns with metronidazole use during pregnancy has not been
found and more recent studies have determined vaginal clindamycin to also be safe. Oral
and vaginal therapy have shown similar cure rates and either treatment route can be used.
The treatment of asymptomatic pregnant women remains unclear. Regarding high risk
women, four out of seven trials showed benefit. Research remains even more unclear
when it comes to asymptomatic BV and low risk pregnancies.
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DISCUSSION
Despite evidence that BV can lead to poor perinatal outcomes, the consensus remains
against a screening and treatment protocol for all pregnant women. Currently, there are no
studies that address the harms of screening specifically. However, there is some concern
regarding misdiagnosis and unnecessary treatment. The lack of recommendation for regular
screening was in part due to treating women with false positive test results. The 2001 USPSTF
review made the following statement regarding asymptomatic treatment.
…2 studies identified in the previous review, bacterial vaginosis-negative women who
received antibiotics had more deliveries before 34 weeks than those not given antibiotics;
this was statistically significant in 1 study and borderline statistically significant in the
other. In addition, 1 study reported a statistically significantly greater frequency of
neonatal sepsis. (Nygren, 2008 p.230)
Of the treatment trials used for the USPSTF recommendations, one found asymptomatic women
who were treated with metronidazole had increased risk of preterm delivery. All the other
treatment trials used for USPSTF recommendations, found no statistically significant adverse
effects to pregnancy outcomes. Many of the studies do not report side effects of the medications
without regard to affecting the outcome of the pregnancy.
Due to variability in a multitude of factors, a generalized recommendation is difficult to
make. There is inconsistency among techniques used for diagnosis, stage of gestation screening
taking place, treatment selection, and route of administration. Ethnicity and socioeconomic
differences among patients also makes providing best practice recommendations difficult. In
discussion, most studies address the fact that if screening is done, it needs to be done early. Some
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even suggest preconception screening and treatment. When looking closely at the studies used to
make these recommendations, much of the screening for asymptomatic BV took place after the
14-16 gestational week window that appears to be pivotal to developing chorioamnionitis.
Koumans et al. (2011) writes, “Vaginal contents are in communication with the uterus until the
fusion of the decidua capsularis with the decidua paretalis at 14-16 weeks of gestation".
(Koumans et al. 2011, p. 1021)
Should all pregnant women be screened for bacterial vaginosis vs only those who are
symptomatic to improve perinatal outcomes?
There were few studies that compared asymptomatic vs symptomatic patients. Nelson et
al. (2008) looked at characteristics related to asymptomatic BV. Being 72% of the sample was
African American, generalizability is limited. They found, compared to the symptomatic
individuals, the asymptomatic group had a higher incidence of Mobiluncus, lower Nugent scores,
as well as a history of more STDs and lower reported stress levels. Interestingly, higher stress
scores were found in both BV positive and BV negative women who reported symptoms.
Uscher-pines (2009) wrote, “…adjusting for high-risk behaviors linked to stress, such as
smoking, removes the independent role of stress of BV development” (Uscher-Pines 2009, p.
516). It appears stress alone cannot be used as a predictor. Nelson et al. (2008) found pregnancy
outcomes appeared similar for PPROM, SPTD, birthweight, and chorioamnionitis among both
asymptomatic and symptomatic participants. Unfortunately, participants were not screened for
co-existing STDs or Candida at time of BV screening and treatment was not disclosed in this
study.
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It is well known that the African American race is a risk factor for BV. Uscher-Pines et
al.(2008) discussed a higher incidence of BV and Mobiluncus species and absence of
Lactobacillus among African American women when compared to whites, symptomatic and
asymptomatic included. Features that may predict higher Mobiluncus and Gardernella levels
were African-American race, single women, and smokers. Lower levels of Lactobacillus were
related to douching and smoking. These two studies only addressed those with a Nugent score of
7-10 and not those who qualified as having intermediate flora. Symptomatology was not
specified as Koumans et al. (2010) completed a retrospective study that found a higher incidence
of abnormal flora and BV among women who were African American, less than 30 years old,
not married, smokers, had more than two children, and had high school education or less.
Lamont (2011) also addressed that Mobiluncus species was associated with a higher Nugent
score and this group had a significantly lower rate of PTD compared to placebo when treated
with clindamycin.
BV appears to have a higher incidence among women with infertility. Van Oostrum et
al. (2013) found 19% prevalence rate of BV in women with infertility and a 39% incidence when
including those with abnormal flora; Nugent score of 4-10. Unfortunately, these studies were
specific to women undergoing in vitro fertilization (IVF). However, this specific cohort of
women gave researchers the opportunity to take samples at implantation and the exact
conception date was known. They found abnormal vaginal flora and BV is more common among
infertility patients compared with antenatal patients from reference population. It also appears
BV is associated with preclinical pregnancy loss; or loss prior to 6 weeks gestation (Ralph,
Rutherford, Wilson 1999).
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It is possible that BV is playing a large role in unexplained cases of infertility. According
to McNamee et al. (2014) if a patient has a history of mid-trimester pregnancy loss (MTL) (loss
between 12 and 24 weeks) a high vaginal swab (HVS) should be completed to check for BV in a
subsequent pregnancy in the first trimester. McNamee et al. (2014) recommend using the Nugent
criteria as this includes intermediate-flora as well. Two large studies showed chorioamnionitis in
94% of spontaneous deliveries before 24 weeks and another with a 77% incidence rate among
spontaneous MTL. Treatment prior to 20 weeks gestation has been shown to have the most
significant reduction in preterm delivery (PTD). In an interview with Sarah Hansen, DNP, NP-C,
CNM, she agreed that knowing who and when to screen and treat is a difficult decision. As she
has developed her practice, she has found the most benefit in screening those who are pregnant
for the first time, those with a history of first trimester miscarriage, and those complaining of
increased discharge. She also questions her patients regarding their sexual history and history of
vaginitis and what, if any symptoms they had with those infections (S. Hansen, personal
communication, November 13, 2018).
The Cochrane review done by Brocklehurst et al. (2013), showed no significant reduction
in preterm birth. The review involving 21 trials found little evidence for screening and treatment
of asymptomatic women to prevent PTB. However, only two studies included intermediate flora;
totaling 894 women. This subgroup did show a 47% reduction in preterm birth less than 37
weeks vs those that did not have altered flora. A randomized control trial showed that
“…treatment of asymptomatic intermediate abnormal vaginal flora and bacterial vaginosis in a
general obstetric population reduces the occurrence of late miscarriage and spontaneous preterm
delivery.” (Ugwumadu et al., 2003, p.983) Antibiotic treatment used was oral clindamycin 300
mg twice daily for 5 days and was given by 17 weeks gestation (Ugwumada et al. 2003).
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Brocklehurst et al. (2013) does address that these results may be attributed to timing of treatment
being earlier in gestation. A significant portion of the Brocklehurst Cochrane review participants
included screening occurring in the 2nd trimester; unknown if this was prior to 14-16 weeks or
not; some as late as 28 weeks.
In asymptomatic patients does screening and treatment decrease the risk of miscarriage
and preterm delivery?
Koumans et al. (2011) found that women from inner-city Syracuse that were treated for
abnormal flora and BV had fewer premature deliveries. The same study also found no
statistically significant difference between women with a negative gram stain and those who
were positive and were treated. This showed that treated BV had the same risk as a pregnant
patient without BV. It is also interesting to note that women who had normal flora prior to 22
weeks gestation and abnormal flora or BV after 22 weeks showed no change in outcomes. The
fusion of the decidua capsularis with the decidua parietalis at 14-16 weeks seals the uterus from
vaginal contents. This may be a reason late treatment has not shown significant outcome
promise. According to this study, re screening and treatment is necessary and should be done
until 16 weeks. Lamont et al. (2011) addresses the route that clindamycin is given plays a large
role in cure of BV. “If microorganisms have gained access to the endometrium/decidua,
clindamycin vaginal cream (CVC) may not be effective at this site and oral therapy may be
beneficial.” (Lamont et al., 2011 p. 185) In comparison of clindamycin and metronidazole,
Lamont et al. (2011) reported clindamycin to have up to a 70.8-90% cure rate compared to 4077% cure rate after 2 days of metronidazole. Haahr et al. (2016), also reported low quality
evidence of treatment with metronidazole for PTB before 37 weeks and made a strong
recommendation against using metronidazole to prevent sPTD. Important to note however, is
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that they were unable to identify any studies using metronidazole prior to 16 weeks gestation.
They also gave a weak recommendation against clindamycin to prevent sPTD; age at gestation
was not discussed here. Vaginal clindamycin is limited to 4% systemic absorption and does
appear safer than oral clindamycin in regard to risk of C. difficile (Lamont et al., 2011).
Sangkomkamhang et al. (2015) conducted a Cochrane review that found antenatal lower
genital tract infection screening and treatment can reduce preterm births up to 50%. The original
study done in Vienna by Kiss et al. (2004) screened for asymptomatic vaginal infections; BV,
candidiasis, and Trichomonas vaginalis on gram stain between 15- & 19-weeks’ gestation. Only
those with a Nugent score of 7-10 were included. BV was treated with 2 gm vaginal clindamycin
and persistent or recurrent infection was treated with 300 mg orally twice daily for seven days.
Some women were found to have concomitant Candida infection, or Candida infection alone
and were treated accordingly. Not all studies used to make recommendations on screening and
treatment recommendations for BV in pregnancy have tested for and treated additional vaginal
infections.
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APPLICABILITY TO PRACTICE
There is still not a clear picture if there should be routine screening and treatment for BV
in all pregnancy. The lack of recommendation for screening and treatment has been due to a few
studies reporting harm after misdiagnosis and treatment. Research has been able to identify risk
factors of developing BV and more research needs to be done in looking at Mobiluncus species,
treatment with clindamycin, and treatment prior to 14-16 weeks when the fusion of the decidua
takes place. The USPSTF guidelines are currently under revision. Since their last publication in
2008; significant studies have been released regarding screening and treatment of asymptomatic
BV; Brocklehurst et al. (2013), Lamont et al. (2011), and Sangkomkamhang et al. (2015) All
three of these reviews found benefit to early screening and treatment. They also found greater
benefit in use of clindamycin over metronidazole. Much of the research does not include if other
infections were present at the time of diagnosis or if the patients have had history of vaginitis or
STDs. It appears Candida, Trichomonas, and other STDs can play a role in miscarriage and also
contribute to the patient being asymptomatic to a BV infection. An increase in sexual partners
appears to have some correlation with the development of BV as well.
More recently, technologic advances have allowed BV to be diagnosed using polymerase
chain reaction (PCR). This is becoming a more popular method used in clinical practice instead
of Amsel’s. PCR has an increased sensitivity and specificity compared to both Amsel and
Nugent criteria. Regarding PCR, Menard et al. (2010) writes, “The molecular tool predicted
bacterial vaginosis with a sensitivity of 100%, a specificity of 93%, a positive predictive value of
73%, and a negative predictive value of 100%”. (Menard et al., 2010, p. 1547) As part of the
results, PCR may be identifying or excluding those incorrectly diagnosed by the other two
methods.
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In my opinion, the development of PCR and its ability to reduce the rate of misdiagnosis
will play a large factor in upcoming recommendations. Newer studies show significant benefit
with early screening and treatment with clindamycin. Further studies are needed that focus on
using PCR for diagnosis, screening early; prior to the closure of the decidua, and clindamycin for
treatment. Additional studies should also be done that look at screening and treatment for
Candida and Trichomonas as well as BV. There is now a better picture of increased risk factors
that include; history of miscarriage, preterm delivery, infertility (unexplained in particular),
African American race, recent history or current smoker, increased sexual partners, and history
of STDs. Knowing this, can help practitioners identify those who would benefit most from
asymptomatic screening. Screening may also be beneficial for those struggling with preclinical
miscarriage. However, few studies have addressed this topic and more research needs to be done.
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